NASDAQ$ZYXIQ

Zynex Inc · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Zynex's financial performance remained steady with revenue and earnings aligning with guidance, and orders increasing year-over-year.

Zynex reported a 13% year-over-year increase in orders for Q3 2024. The company's revenue and earnings were within the provided guidance. They also received FDA clearance for their new TensWave device.

  • Q3 2024 orders increased 13% year-over-year.
  • Q3 2024 net revenue reached $50.0 million.
  • Q3 2024 net income was $2.4 million, with a diluted EPS of $0.07.
  • Q3 2024 cash flow from operations totaled $7.1 million.

Headline financials

Total Revenue

$50M

Previous: $49.9M+0.1%
EPS

$0.07

Previous: $0.10-30.0%
Capital Expenditures

-$362K

Previous: -$630K+42.5%
Free Cash Flow

$9.91M

Previous: $10.9M-9.4%
Net Income

$2.38M

Previous: $3.59M-33.7%
Operating Income

$3.8M

Previous: $5.49M-30.7%
Gross Profit

$39.8M

Previous: $40.4M-1.4%
Cash & Equivalents

$37.6M

Previous: $42.5M-11.5%
Total Assets

$126M

Previous: $151M-16.8%
Stock-Based Comp

$770K

Previous: $654K+17.7%

Revenue & EPS history

Zynex · Revenue · Quarterly

$50M

Q3 2024+0.1%vs Q3 2023
Beat estimate in 7 of 16 quarters(44%)
ActualEstimate

Revenue by segment

Zynex · $49.9M total across 2 segments · Q3 2023

  • Supplies
    $33.1M
  • Devices
    $16.9M

Forward guidance

Zynex anticipates continued diversification of pain management revenue with new therapy products and expects to return to approximately 20% top-line growth in the pain management division in 2025. Fourth quarter 2024 revenue is estimated to be at least $53.6 million with Diluted EPS is estimated to be at least $0.09. The Company expects 2024 net revenue of at least $200 million and Diluted EPS is expected to be at least $0.20 per share.

Tailwinds

  • Introduction of new therapy products to diversify revenue stream.
  • Aggressive product promotion by the salesforce to ensure sustained profitable growth.
  • Expected return to approximately 20% top-line growth in the pain management division in 2025.
  • Fourth quarter 2024 revenue is estimated to be at least $53.6 million
  • Fourth quarter Diluted EPS is estimated to be at least $0.09

Headwinds

  • No specific negatives were mentioned in the provided report.
  • However, general risks include obtaining CE marking of new products, acceptance of products by doctors and hospitals,
  • competition from larger entities, keeping pace with technological changes,
  • dependence on reimbursement from health insurance companies, and reliance on third-party manufacturers.
  • Economic factors, such as interest rate fluctuations

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

+0.4%

Avg return

Earnings day

-1.8%

Avg return

5 days after

-6.5%

Avg return

30 days after

46%

29 / 63 earnings

Positive

+38.5%

Q3 2014

Best reaction

-51.6%

Q1 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2024-51.3%
Q3 2025+0.0%+0.0%-98.2%
Q2 2025+0.0%+0.0%+0.0%
Q1 2025-25.6%+0.0%+0.0%
Q3 2024+9.1%+0.0%+0.0%
Q2 2024-11.4%+0.0%+0.0%
Q1 2024+2.8%+0.0%+0.0%
Q4 2023-8.8%+0.0%+0.0%
Q3 2023+17.5%+0.0%+0.0%
Q2 2023+3.3%+0.0%+0.0%
Q1 2023+2.5%+0.0%+0.0%
Q4 2022+16.7%+0.0%+0.0%
Q3 2022+15.0%+0.0%+0.0%
Q2 2022+13.3%+0.0%+0.0%
Q1 2022-8.6%+0.0%+0.0%
Q4 2021-1.7%+0.0%+0.0%
Q3 2021+10.0%+0.0%+0.0%
Q2 2021-19.3%+0.0%+0.0%
Q1 2021-9.2%-12.0%-6.3%
Q4 2020-21.2%-22.4%-18.8%
Q3 2020-6.5%
Q2 2020-6.0%
Q1 2020-1.1%
Q4 2019+3.1%
Q3 2019-7.9%
Q2 2019+9.8%
Q1 2019+7.9%
Q4 2018-11.1%
Q3 2018+3.4%
Q2 2018-3.3%
Q1 2018+4.5%
Q4 2017-20.7%
Q3 2017+6.6%
Q2 2017+34.6%
Q1 2017-5.6%
Q4 2016+9.7%
Q3 2016+23.1%
Q2 2016+34.8%
Q1 2016+0.0%
Q4 2015+0.0%
Q3 2015-4.3%
Q2 2015-5.4%
Q4 2014+0.0%
Q1 2015+0.0%
Q3 2014+38.5%
Q2 2014+2.2%
Q1 2014-0.2%
Q4 2013-3.6%
Q3 2013+13.6%
Q2 2013+7.1%
Q1 2013+0.0%
Q4 2012+3.4%
Q3 2012+5.6%
Q2 2012-5.1%
Q1 2012-6.3%
Q4 2011+0.0%
Q3 2010+12.9%
Q3 2011+12.9%
Q2 2011+1.1%
Q1 2011-8.2%
Q4 2010+0.0%
Q2 2010+2.0%
Q1 2010-51.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro